Cetera Investment Advisers Reduces Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cetera Investment Advisers reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,994 shares of the company's stock after selling 1,841 shares during the quarter. Cetera Investment Advisers' holdings in IDEXX Laboratories were worth $7,439,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sax Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories by 76.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after acquiring an additional 617 shares in the last quarter. Hantz Financial Services Inc. increased its position in IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after purchasing an additional 800 shares during the period. Paragon Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after purchasing an additional 782 shares in the last quarter. Manitou Investment Management Ltd. raised its holdings in shares of IDEXX Laboratories by 491.0% in the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock valued at $21,582,000 after purchasing an additional 43,369 shares in the last quarter. Finally, Fiera Capital Corp lifted its position in shares of IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after purchasing an additional 15,463 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Morgan Stanley boosted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Finally, Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $524.75.

IDEXX Laboratories Stock Up 1.2%

Shares of IDXX stock traded up $6.11 during trading hours on Friday, reaching $518.10. 524,927 shares of the company's stock were exchanged, compared to its average volume of 648,426. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $547.22. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market cap of $41.67 billion, a PE ratio of 48.56, a PEG ratio of 3.41 and a beta of 1.52. The stock's fifty day moving average price is $429.46 and its two-hundred day moving average price is $430.94.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.71 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.